# FdaApprovalPulse benchmark report

> As of 2026-11-04, FdaApprovalPulse holds 1,969 public records from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration). The largest group is Drug labeling or REMS supplement with 1,180 (60%). Computed from the live dataset and updated on every refresh.

## By location

| Group | Records |
|---|---|
| Unknown | 1614 |
| CA | 110 |
| MN | 61 |
| MA | 37 |
| OR | 20 |
| TX | 18 |
| AZ | 18 |
| IL | 9 |
| MD | 9 |
| TN | 8 |
| PA | 7 |
| FL | 6 |
| WA | 6 |
| WI | 5 |
| MO | 5 |

## By category

| Group | Records |
|---|---|
| Drug labeling or REMS supplement | 1180 |
| PMA supplement (device change) | 367 |
| Generic drug approval (ANDA) | 196 |
| Drug efficacy supplement (new indication or use) | 77 |
| Drug manufacturing (CMC) supplement | 55 |
| New drug application (NDA) | 41 |
| PMA original approval (new class III device) | 24 |
| Biologic license (BLA) | 17 |
| Other drug supplement | 12 |

Source: https://zalwin.com/reports/fdaapprovalpulse-benchmark (updated 2026-11-04).